Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

12.48$0.96 8.33%
At close       04:00 PM   

Stock Snapshot

11.52
Prev. Close
11.71
Open
210.16M
Market Cap
589040.00
Number of Shares
11.60
Day Low
13.10
Day High
12.48
-
P/E Ratio
16.54M
Free Float in %
-2.30
EPS 2021
2.54
Book Value per Share
2.62
Cash Flow per Share
aTyr Pharma, Inc. (LIFE)
aTyr Pharma, Inc. (LIFE) stock rallied over 8.33% intraday to trade at $12.48 share on NASDAQ. The stock opened with a gain of % at $11.71 and touched an intraday high of $13.10, rising 13.72% against the last close of $11.52. The stock went to a low of $11.60 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$5.60$5.48$5.60$5.44119,572
2021-09-03$5.44$5.49$5.50$5.387,560,000
2021-09-02$5.47$5.48$5.52$5.409,460,000
2021-09-01$5.46$5.46$5.52$5.3714,010,000
2021-08-31$5.49$5.51$5.62$5.3522,220,000
2021-08-30$5.38$5.49$5.54$5.2315,080,000
2021-08-27$5.15$5.32$5.40$5.1514,340,000
2021-08-26$5.25$5.19$5.33$5.1611,340,000
2021-08-25$5.08$5.25$5.28$5.0014,830,000
2021-08-24$4.91$5.09$5.12$4.9116,320,000
2021-08-23$4.65$4.91$4.92$4.5919,960,000
aTyr Pharma, Inc.
3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States

http://www.atyrpharma.com
858 731 8389
Employees
43
Sector
Healthcare
Sales or Revenue
2.20M
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam